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Abstract
Background: RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It
mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or
indirectly through vascular normalization and increased T-lymphocyte infiltration. With multiple additional
mechanisms of action including upregulation of oxidative stress, depletion of GSH and NADPH, anti-angiogenesis
and epigenetic modulation, RRx-001 is being studied as a radio- and chemo-sensitizer to resensitize tumors to
prior therapy and to prime tumors to respond to radiation, chemotherapy and immunotherapy in combination
therapy studies. Here, we identified another mechanism, viral mimicry, which refers to the “unsilencing” of
epigenetically repressed viral genes present in the tumor that provokes an immune response and may contribute
to the anticancer activity of RRx-001.
Results: RRx-001 inhibited the growth of colon cancer cells (HCT 116) and decreased levels of the DNA
methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner. Treatment of HCT 116 cells with
0.5 μM RRx-001 for 24 h significantly increased transcripts of interferon (IFN)-responsive genes and this induction
was sustained for up to 4 weeks after transient exposure to RRx-001. ELISA assays showed that RRx-001 increased
secretion of type I and III IFNs by HCT 116 cells, and these IFNs were confirmed to be bioactive. Transcription of
endogenous retrovirus ERV-Fc2 and LTRs from the ERV-L family (MLT2B4 and MLT1C49) was induced by RRx-001.
The induction of ERV-Fc2-env was through demethylation of ERV-Fc2 LTR as determined by methylation-specific
polymerase chain reaction and combined bisulfite restriction analysis. Immunofluorescence staining with J2
antibody confirmed induction of double-stranded RNA.
Conclusions: Transient exposure of HCT 116 cells to low-dose RRx-001 induced transcription of silenced retroviral
genes present in the cancer cell DNA with subsequent synthesis of IFN in response to this “pseudo-pathogenic”
stimulus, mimicking an antiviral defense. RRx-001-mediated IFN induction may have the potential to improve the
efficacy of immunotherapies as well as radiotherapy, standard chemotherapies and molecularly targeted agents
when used in combination. The striking safety profile of RRx-001 in comparison to other more toxic epigenetic
and immunomodulatory agents such as azacitidine makes it a leading candidate for such clinical applications.
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Background
Immunotherapy has shown remarkable anticancer activ-
ity, with several immunotherapeutic modalities already
approved by the Food and Drug Administration (FDA)
for treating cancer patients [1]. Nevertheless, current
immunotherapies only benefit 20–30% of patients in
susceptible tumor types such as melanoma, non-small
cell lung cancer and renal cell carcinoma. An emerging
theme is that a relatively small percentage of treated pa-
tients demonstrate complete pathological remission or
durable response, stimulating great interest in combining
immunotherapy with chemotherapy and radiation [2, 3].
An even more attractive strategy to further improve the
efficacy of cancer immunotherapy and to increase long-
lasting disease control is to combine immunotherapy with
agents that improve innate and/or adaptive immune
responses. Along this line, of the many possible strategies
being explored, combining immunotherapy with epigenetic
agents is believed to hold considerable promise because of
the well-established immunomodulatory potential of
epigenetic drugs [4]. As discussed in a recent news feature
in Nature Medicine, multiple global trials are underway to
test combinations of immune checkpoint inhibitors and
epigenetic therapies in solid tumors [5]. The epigenetic
drugs include FDA-approved inhibitors of histone deacety-
lases (e.g., entinostat) and DNA methylation [e.g., azaciti-
dine (5-AZA) and decitabine (5-AZA-CdR)] [4, 5].
A new paradigm to restore impaired immune function
in tumors is the induction of viral mimicry by DNA
methyltransferase inhibitors [6]. Viral mimicry is a term
that, in an epigenetic context, refers to the transcription
of silenced “endogenized” viral genes present in the
tumor DNA and subsequent translation of viral proteins
in the absence of an actual infection, which serves to
excite a “vaccine-like” host immune response. Roulois et
al. demonstrated that transient treatment of colon
cancer cells with 5-AZA-CdR increased the levels of
cytoplasmic double-stranded RNA (dsRNA) from
endogenous transcripts including human endogenous
retroviruses (ERVs), which in turn induced the expres-
sion of interferon (IFN)-stimulated genes (ISGs), includ-
ing type III IFNs [7]. One striking consequence of this
induction of viral mimicry by 5-AZA-CdR was the de-
creased frequency of cancer-initiating cells [7]. Similarly,
Chiappinelli et al. showed that 5-AZA and 5-AZA-CdR
triggered cytosolic sensing of dsRNA in ovarian cancer
cells, causing a type I IFN response and apoptosis [8].
These studies pointed to a major role of the innate im-
mune response in the antitumor effect of DNA
demethylating agents. Moreover, because IFNs have been
implicated in promoting strong immune responses, it is
not surprising that in these studies, 5-AZA and 5-AZA-
CdR sensitized checkpoint inhibitor-based immunother-
apy in preclinical cancer models [7, 8].
In this study, we compared the novel immunomodula-
tory anticancer agent RRx-001 to 5-AZA in terms of
ability to induce viral mimicry. Previously, we have
shown that RRx-001 generates reactive oxygen and
nitrogen species and nitric oxide, elicits changes in intra-
cellular redox status, modulates tumor blood flow, hyp-
oxia and vascular function, and triggers apoptosis in
cancer cells [9–12]. For example, when administered to
mice as a single agent, RRx-001 exhibited greater cyto-
toxicity than cisplatin or tirapazamine under hypoxic
conditions [9]. When compared with cisplatin, RRx-001
was better tolerated at submaximal doses, yielding
significant tumor growth inhibition in the absence of
systemic toxicity [9]. Moreover, RRx-001 significantly
decreased DNMT1 and DNMT3A protein expression in
a dose- and time-dependent manner in murine SCC VII
cancer cells and induced demethylation of genes import-
ant in pathways relevant to cancer [13]. Finally, RRx-001
activates Nrf2-ARE antioxidant signaling pathways in
tumor cells and therefore measurement of Nrf2-mediated
activation of downstream target genes through ARE sig-
naling may constitute a useful molecular biomarker for
the early prediction of response to RRx-001 treatment and
thereby guide therapeutic decision-making [10].
Currently, RRx-001 is undergoing evaluation as a single
chemotherapeutic agent to resensitize tumors to prior
therapy and to prime tumors to respond to radiation,
chemotherapy and immunotherapy in combination ther-





These clinical trials have demonstrated the clear-cut
safety advantage of RRx-001, which, unlike 5-AZA and
other epigenetic therapies, is non-myelosuppressive and
has minimal to no systemic toxicity [14, 15]. Likewise,
despite the therapeutic potential of checkpoint inhibi-
tors such as ipilimumab or nivolumab, immune-related
adverse events such as diarrhea are not uncommon
with these agents, occurring in 16–27% of treated
patients and in 55% when used in combination [16]; in
contrast, the benign toxicity profile of RRx-001 [14]
facilitates combination with other therapies. We exam-
ined the effects of transient exposure of HCT 116 cells
to RRx-001 versus 5-AZA on expression of IFNs and
ISGs as well as dsRNAs and ERVs, and whether these
effects were mediated by DNA demethylation. We
found that transient exposure of HCT 116 cells to low-
dose RRx-001 induced transcription of silenced
retroviral genes present in the cancer cell DNA with
subsequent synthesis of IFN and ISGs in response to
this “pseudo-pathogenic” stimulus, mimicking an anti-
viral defense.
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Methods
Reagents
RRx-001 was obtained from Orbital ATK (Dulles, VA,
USA). The DNA methyltransferase inhibitor 5-azacytidine
(5-AZA) was purchased from Sigma-Aldrich (St. Louis,
MO, USA). Ruxolitinib was purchased from Selleck Chem-
ical (Houston, TX, USA). RRx-001, 5-AZA and ruxolitinib
solutions were freshly prepared on the experimental day by
dissolving in DMSO and then diluting with cell culture
medium. The final concentration of DMSO was 0.025%.
Cell culture and treatments
Human HCT 116 cells (gift of Dr. Calvin Kuo at Depart-
ment of Medicine, Stanford University, Stanford, CA,
USA) were authenticated by the Genomic Resources Core
Facility (GRCF) at John Hopkins University (Baltimore,
MD, USA) using a short-tandem repeat (STR) analysis.
The cells were also determined to be mycoplasma nega-
tive by GRCF. Murine SCC VII and human HCT 116 cells
were grown in DMEM medium supplemented with 10%
fetal calf serum and 100 μg/ml gentamycin in a 37 °C
humidified incubator with a mixture of 95% air and 5%
CO2. Exponentially growing cells were treated with 5-
AZA, RRx-001, or 0.025% DMSO as a vehicle control for
1 to 3 days. Media containing RRx-001, 5-AZA, or DMSO
were replaced daily over the 3-day period.
In vitro cytotoxicity assay
Cell counting kit-8 (CCK-8), a modified MTT assay with 2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium (Dojindo Molecular Technologies,
Rockville, MD, USA), was used to measure the cytotoxicity
of RRx-001. Cells were inoculated into 96-well plates and in-
cubated overnight. Freshly prepared solutions of RRx-001
were added in the final concentrations ranging from 0.1 to
1000 μM in 200 μL of loading volume. Three days later,
plates were washed with phosphate-buffered saline (PBS)
and refilled with 100 μL of phenol red-free growth medium.
CCK-8 solution was added and after a 2-h incubation at 37 °
C, the optical absorbance of wells was measured at a wave-
length of 450 nm with a microplate reader (Molecular
Devices, Sunnyvale, CA, USA). Cell viability was calculated
as the percentage of the optical density of the treated cells
to that of untreated control cells.
Western blots
After treatment with DMSO, 0.5 μM 5-AZA, or 0.5-5 μM
RRx-001 for 1–3 days, cells were washed twice with cold
PBS and lysed in RIPA buffer (Sigma-Aldrich, St. Louis,
MO, USA) for preparation of whole cell lysates. Medium
was changed daily with fresh drug during treatment. Pro-
tein contents were quantified using a Bio-Rad Quick Start
protein assay kit (Bio-Rad Laboratories, Hercules, CA,
USA). Samples containing equal amounts of total protein
(20 μg) were separated on 10% SDS-PAGE gels and trans-
ferred onto PVDF membranes. The membranes were
blocked with 5% non-fat milk and probed with primary
antibodies against DNMT1 (1:500, Cell Signaling Tech-
nology, Danvers, MA, USA), DNMT3a (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and β-actin (1:500,
Santa Cruz Biotechnology), and HRP-conjugated second-
ary antibodies (1:2500, Santa Cruz Biotechnology). The
immunoreactive proteins were detected with ECL plus
chemiluminescence detection reagents (Amersham Biosci-
ences, Little Chalfont, UK). The Western blot analyses
were run at least twice for each molecular marker, unless
otherwise indicated.
Quantitative polymerase chain reaction (qPCR)
RNA was isolated using Trizol reagent according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA,
USA. Two micrograms of DNase-treated RNA were
used to synthesize cDNA using PrimeScript RT reagent
kit (Takara, Mountain View, CA, USA), and one twenti-
eth of the resulting cDNA was subjected to PCR amplifi-
cation using SYBR Green PCR Master Mix (Invitrogen).
The level of RPLP0 RNA was used as an internal control
to normalize expression levels of genes of interest. PCR
amplification was performed on the Mx3005P QPCR
system (Stratagene, San Diego, CA, USA). Primers used
in this study are listed in Table 1.
ELISA
Levels of type I IFN (IFN-β) and type III IFN (IL-29/IL-
28B) were determined using a VeriKine Human IFN-beta
ELISA Kit (PBL Assay Science, Piscataway Township, NJ,
USA) and a Human IL-29/IL-28B (IFN-lambda 1/3) Duo-
Set ELISA Kit (R&D Systems, Minneapolis, MN, USA)
according to manufactures’ instructions, respectively. Fifty
microliters of media were used for each well and triplicates
were evaluated for each sample.
Immunofluorescence staining
Cells were fixed with 2% paraformaldehyde in PBS for
10 min, permeabilized with 0.5% Triton X-100 in PBS
for 10 min, and blocked with 10% horse serum in PBS
for 1 h. Cells were then stained with primary antibody
against double-stranded RNA (J2, 1:200, Scicons, Szirák,
Hungary), and goat anti-mouse Alexa 555-conjugated
secondary antibody (1:1000, Invitrogen). To quantify J2-
negative cells, five random fields were selected and J2-
negative cells were counted.
Methylation assays
Genomic DNA was bisulfite-converted using the EZ
DNA Methylation Kit (Zymo Research, Irvine, CA,
USA). Methylation-specific PCR was performed as previ-
ously described for the ERV-Fc2-env gene [8]. COBRA
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(Combined Bisulfite Restriction Analysis) was performed
at the ERV-Fc2 LTR located on chromosome 11 as pre-
viously described [8]. Bisulfite-treated DNA was ampli-
fied and digested with the AciI enzyme. Unmethylated
DNA was not digested and remained intact as a 199 bp
band. Methylated DNA was digested into two bands
(155 and 44 bp). Bands and restriction fragments were
resolved on 2% agarose gels, stained with ethidium
bromide, and photoimaged with a gel imaging system.
Signal intensity was quantified using ImageJ software
(https://imagej.net). Primers for methylation-specific
PCR and COBRA are listed in Table 1.
Statistical analysis
Two-tailed Student’s t test was used for two-arm experi-
ments. A p < 0.05 was considered significant. Statistical
tests were performed with Excel Stats.
Results
RRx-001 inhibited growth of HCT 116 cells
In vitro antiproliferative activity of RRx-001 was previ-
ously demonstrated in a panel of 12 cancer cell lines,
with IC50 values ranging from 1.8–6.0 μM [9]. Using the
same cytotoxicity assay as in the previous study [9], we
found that HCT 116 colon cancer cells showed an IC50
of 5.03 μM in response to RRx-001, whereas SCC VII
(murine squamous cell carcinoma), the most responsive
cell line among the 12 cancer cell lines previously tested,
had an IC50 of 1.8 μM (Fig. 1a). These results demon-
strated that HCT 116 cells were responsive to the
growth-inhibitory activity of RRx-001.
RRx-001 downregulated DNMT1 and DNMT3a proteins in
HCT 116 cells
We previously showed that RRx-001 significantly decreased
protein levels of the DNA methyltransferases DNMT1 and
DNMT3a in SCC VII cells in a dose- and time-dependent
manner [13]. Here, we investigated the effect of RRx-001 on
DNMT1 and DNMT3a in HCT 116 cells. Figure 1b shows
protein levels of the two DNA methyltransferases in
cells treated with 0.5 μM 5-AZA or 0.5–5 μM RRx-001
for 24–72 h. As anticipated, the levels of both proteins
were dramatically decreased by 0.5 μM 5-AZA as early
as 24 h after treatment, as reported in previous publica-
tions [17]. RRx-001 also decreased levels of DNMT1
and DNMT3a in a time and dose-dependent manner,
confirming that RRx-001 is a DNA methyltransferase
inhibitor. However, downregulation of DNMTs by RRx-
001 required higher concentrations and longer expos-
ure compared to 5-AZA. Whereas DNMT1 decreased
to <5% of control by 24 h after treatment with 0.5 μM
5-AZA, equivalent reduction of DNMT1 by RRx-001
did not occur until 72 h after treatment with 5 μM
RRx-001. DNMT3a was also reduced to a lesser extent
by RRx-001 compared to 5-AZA. Altogether, these
results suggest that there are both similarities and
differences in the mechanisms of action of these two
drugs.
Transient exposure of HCT 116 cells to RRx-001 resulted
in sustained induction of ISGs
The ability of RRx-001 to induce four selected ISGs
(IRF7, OASL, ISG15, and DDX58) in HCT 116 cells was
Table 1 Primers used in qPCR















Env-Fc2 methylated CGGGCGAGGTTTATTGGTTCG CGCYTATTCCCWTTTATTCCCG
Env-Fc2 unmethylated TGGGTGAGGTTTATTGGTTTGTAGG CACYTATTCCCWCCATTTATTCCCA
Env-Fc2 COBRA GTATAATGGGGAAAAATGGAA ACTTCCCTAACCCTCCC
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compared to that of 5-AZA. Cells were transiently
(24 h) treated with 0.5–5 μM RRx-001 or 0.5 μM 5-AZA
and subsequently maintained in drug-free medium for
an additional 7 days. RNA transcripts of all 4 genes were
significantly increased by 0.5 μM 5-AZA as measured by
qPCR (Fig. 2a), reproducing previous findings [7, 8].
Notably, 0.5 μM RRx-001 also significantly increased
transcripts of all 4 genes, to levels equivalent to or even
higher than induced by 5-AZA (Fig. 2b). Induction of
the 4 genes by 2 μM RRx-001 tended to be less than that
with 0.5 μM, and none of the transcripts were signifi-
cantly increased by 5 μM RRx-001 (data not shown),
similar to our previous finding that RRx-001 induced
epigenetic effects at lower rather than higher concentra-
tions [13]. In this regard, RRx-001 is similar to 5-AZA,
which in some cases has elicited a greater effect on
methylation at lower concentrations [18, 19].
To determine whether the effect of RRx-001 on ex-
pression of ISGs in HCT 116 cells was sustained, we cul-
tured the cells for 4 weeks after transient (24 h)
exposure to 0.5 μM RRx-001 and quantified transcripts
of the 4 ISGs at weeks 2, 3, and 4. Cells transiently
treated with 0.5 μM 5-AZA were similarly maintained
and evaluated. As shown in Fig. 2a, all 4 ISGs remained
at significantly elevated levels at weeks 2, 3, and 4 after
transient exposure to 5-AZA. All 4 genes at week 2, and
3 of 4 genes at week 3, remained elevated after transient
exposure to RRx-001 (Fig. 2b), whereas only 1 of 4 genes
still showed significantly increased expression at week 4
(Fig. 2b). These results showed that transient treatment
with RRx-001 resulted in sustained elevated expression
of ISGs in HCT 116 cells, albeit with a less long-lasting
effect than that of 5-AZA.
RRx-001 induced bioactive type I and type III IFNs
To determine which IFNs might be responsible for the
induction of ISGs by RRx-001 in HCT 116 cells, we ex-
amined RNA and protein levels of several type I and
type III IFNs. Secreted protein levels of a type I IFN,
IFNβ, were measured by ELISA after treatment of HCT
116 cells with 0.5 μM RRx-001 or 5-AZA. Both
compounds significantly increased the amounts of IFNβ
secreted 4 days after transient (24 h) treatment (Fig. 3a).
Levels of secreted IFNβ remained significantly elevated
7 days after treatment with 5-AZA but not RRx-001
(Fig. 3a). Both compounds also significantly increased
the amounts of type III IFN [IFNλ 1/3 (IL-29/IL-28B)]
secreted 4 days after transient treatment (Fig. 3b). The
induction of secreted IFNλ 1/3 was more prominent
7 days after treatment with 5-AZA or RRx-001 (Fig. 3b).
Finally, transcripts of two type III IFNs, IL28A and IL29,
showed a modest, but significant, increase after transient
treatment with 5-AZA or RRx-001 (Fig. 3c). These re-
sults suggest that RRx-001 induced ISGs through upreg-
ulation of both type I and III IFNs, similarly to 5-AZA.
To determine whether induction of IFNs by RRx-001
involved JAK, cells were treated with ruxolitinib, a JAK1/
JAK2 inhibitor, in conjunction with RRx-001 or 5-AZA.
Fig. 1 RRx-001 inhibited cell growth and DNMT1 and DNMT3a expression in HCT 116 cells. Exponentially growing cells were treated with 5-AZA,
RRx-001 or 0.025% DMSO as a vehicle control for 1 to 3 days. Media containing RRx-001, 5-AZA, or DMSO were replaced daily over the 3-day
period. a Concentration-survival curve of HCT 116 cells treated with RRx-001. SCC VII cells were used as a positive control. Data are mean ± SD
from 3 independent experiments. b Protein levels of DNMT1 and DNMT3a in HCT 116 cells treated with RRx-001 as determined by Western blot.
β-actin was used as an internal control for sample loading. 5-AZA was used as a positive control for inhibition of DNMT1 and DNMT3a expression.
Bar graphs show the relative expression of DNMT1 and DNMT3a in treated cells compared to control cells
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Ruxolitinib blocked the induction of ISGs by 5-AZA, as
previously reported [7, 8], and also significantly blocked
induction of 2 of 4 ISGs by RRx-001 (Fig. 3d). These
results suggest that induction of IFNs and upregulation of
ISGs in cells treated with RRx-001 is mediated by JAK.
To determine whether the secreted IFNs induced by
5-AZA and RRx-001 were bioactive, HCT 116 cells were
cultured in medium previously conditioned by HCT 116
cells maintained for 7 days after transient exposure to
0.5 μM 5-AZA or RRx-001. Transcripts of the 4 ISGs
were significantly increased in cells cultured in condi-
tioned medium compared to control (Fig. 3e), indicating
that the secreted IFNs induced by 5-AZA and RRx-001
were bioactive.
RRx-001 induced dsRNA and LTRs from the ERV-L family
in HCT 116 cells
The J2 antibody was used to monitor the presence of
dsRNA in HCT 116 cells after treatment with 5-AZA or
RRx-001. Cells were transiently (24 h) treated with drugs
and maintained for an additional 5 days in drug-free
medium. 5-AZA uniformly increased immunofluores-
cence staining with J2 in ~100% of cells (Fig. 4a). RRx-001
similarly increased J2 staining in the majority of cells, indi-
cating that RRx-001, like 5-AZA, induced expression of
dsRNA (Fig. 4a). Notable, however, was the approximately
14% of J2-negative cells among the population treated
with RRx-001 (arrows in Fig. 4a) but not with 5-AZA,
suggesting that some HCT 116 cells were less responsive
to the induction of dsRNA by RRx-001.
To determine whether the increase in dsRNA was at-
tributable to increased expression of endogenous retrovi-
ruses (ERVs), we measured transcript levels of MTL1C49
and MTL2B4, two ERVs among those found to be most
highly induced by 5-AZA treatment of HCT 116 cells in a
previous study [7]. Indeed, expression of both ERVs was
increased by 0.5 μM 5-AZA (Fig. 4b). An equivalent con-
centration of RRx-001 also significantly increased tran-
scripts of both ERVs, although to somewhat lesser levels
(Fig. 4b). These findings, together with the increase in J2
staining, show that RRx-001, like 5-AZA, induces expres-
sion of LTRs from the ERV-L family (MLT2B4 and
MLT1C49) by transient treatment of HCT 116 cells.
RRx-001 demethylated ERV-Fc2 LTR
To determine whether induction of ERV expression by
RRx-001 was mediated by DNA demethylation, we ex-
amined the methylation status of ERV-Fc2-env, a mem-
ber of the extended ERV-F/ERV-H family. Cells were
transiently (24 h) treated with drugs and maintained for
an additional 5 days in drug-free medium. Consistent
with the observed increase in ERV-Fc2-env transcripts
after transient exposure to 0.5 μM RRx-001 or 5-AZA as
determined by qPCR (Fig. 5a), treatment of HCT 116
with 5-AZA or RRx-001 resulted in increased levels of
unmethylated DNA at the CpG loci of ERV-Fc2 LTR as
measured by methylation-specific PCR (Fig. 5b) and
COBRA (Fig. 5c). These results suggest that the induc-
tion of dsRNA by RRx-001 is mediated by DNA demeth-
ylation of ERV-Fc2 LTR.
Discussion
One of the major problems with current anticancer mo-
dalities is a lack of specificity that often results in systemic
and dose-limiting toxicities. The low inherent toxicity of
RRx-001 and the selective red blood cell-mediated
localization of its cytoactive metabolites in tumors [11] set
RRx-001 apart from current anticancer modalities such as
traditional chemotherapeutics, targeted small molecule
Fig. 2 Transient treatment with RRx-001 induced a sustained IFN
response in HCT 116 cells. Expression of IFN-stimulated genes (ISGs)
over the course of 4 weeks in response to 24 h of treatment with
0.5 μM 5-AZA (a) or RRx-001 (b). Transcript levels of ISGs (ISG15, IRF7,
OASL, and DDX58) were determined by qPCR 7 days after treatment.
Upregulation of gene expression observed in 5-AZA- treated cells
was statistically significant at all time points. Gene expression
changes observed in RRx-001-treated cells that were not significantly
different from DMSO-treated cells were marked by # and those that
were significantly downregulated by ##
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Fig. 3 RRx-001 induced IFN response through upregulation of type I and III IFN expression and JAK/STAT pathway. Cells were transiently (24 h)
treated with 0.5 μM RRx-001 or 0.5 μM 5-AZA and subsequently maintained in drug-free medium for an additional 7 days. RRx-001 induced a sig-
nificant increase in type I IFN (IFN-β) (a) and type III IFN (IL-29/IL-28B) (b) secretion into culture medium by HCT 116 cells as measured by ELISA.
Transcript levels of IL29/IL28A were also increased as determined by qPCR (c). ISGs (IFI27, IFi44, IFI44L, and IFI6) were upregulated by 5-AZA and
RRx-001 but blocked by the JAK/STAT inhibitor ruxolitinib (rux) at 2 μM concentration (d). Expression of ISGs (IRF7, ISG15, DDX58, and OASL) was
also upregulated in HCT 116 cells cultured in conditioned medium containing secreted IFNs induced by 5-AZA and RRx-001 as determined by
qPCR (e)
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therapies, radiation, epigenetic agents, and even check-
point inhibitors. Several studies have shown that RRx-001
possesses diverse, pleiotropic mechanisms of action
including reeducation of tumor associated macrophages
from an M2 to an M1 phenotype, upregulation of oxida-
tive stress, GSH and NADPH depletion, vascular
normalization, and epigenetic modulation [9–13, 20] that
may enhance the antitumor immune response. In this
study in HCT 116 cells, we identified an additional mech-
anism underlying immunomodulatory activity of RRx-001,
involving stimulation of a type I IFN response through
transcriptional reactivation of remnant ERVs that are
present in the tumor DNA. The translation of these viral
proteins simulates an infection and an immune response
to this “pseudo-infection” ensues. The induction of IFN
signaling through the JAK-STAT pathway with RRx-001
was long-term and likely mediated by reduction of DNA
methyltransferases DNMT1 and DNMT3a, which in turn
led to demethylation of ERV-Fc2 LTR. Interestingly, in a
dose-dependent inverse effect that is characteristic of
epigenetic inhibitors, lower doses of RRx-001 were associ-
ated with greater induction of ISGs. This induction of a
“pseudo-infected” state with the subsequent production of
ISGs may serve to improve the efficacy of immunother-
apies such as checkpoint inhibitor-based therapies
recently approved by FDA including anti-CTL4 and anti-
PD-1/PDL-1 as well as other small molecules and stand-
ard chemotherapies.
The ability of epigenetic drugs to improve treatment with
immune checkpoint inhibitors has been demonstrated in a
variety of preclinical models. Kim et al. showed that co-
treatment with anti-CTLA-4 and epigenetic-modulating
drugs, i.e., 5-AZA and entinostat, a class I HDAC inhibitor,
markedly improved treatment outcomes, curing more than
80% of mice bearing colorectal or breast cancers [21]. In
addition, combined treatment with anti-CTLA-4 and
either 5-AZA-CdR [22] or the second-generation DNMT
inhibitor guadecitabine [23] significantly reduced the
growth of poorly immunogenic syngeneic grafts of murine
mammary carcinoma TS/A and of mesothelioma AB1 with
respect to treatment with the single agents. In the B16-F10
mouse melanoma model, multiple combinations of low-
dose 5-AZA directly enhanced tumor responses to anti-
CTLA4 immune checkpoint therapy [8]. These studies
support the addition of epigenetic agents to immune
checkpoint inhibitor therapies in clinical trials to increase
their spectra of activity. Two examples of such clinical
trials are the ongoing phase Ib trial NIBIT-M4
(EUDRACT 2015-001329-17), combining guadecitabine
and an anti-CTLA-4 monoclonal antibody (ipilimumab)
in metastatic melanoma, and the randomized phase II trial
NCT01928576 combining an “epigenetic priming” with
azacytidine/oral azacytidine, given alone or in association
with entinostat, with anti-PD-1 immunotherapy in
patients with non-small cell lung cancer. Interestingly, Liu
et al. recently reported that vitamin C increases viral mim-
icry induced by low doses of 5-AZA-CdR in vitro, suggest-
ing that correction of vitamin C deficiency in cancer
patients may improve responses to epigenetic therapy with
DNMT inhibitors [24].
Our study strengthens the rationale to combine RRx-
001 with immunotherapy to enhance its efficacy. Similar
to 5-AZA, RRx-001 is a DNA demethylating agent that
inhibits DNMT1 and DNMT3a expression, but, unlike
5-AZA, it is non-myelosuppressive, which means that
the dose modifications, interruptions, delays, reductions,
Fig. 4 RRx-001 upregulated ERV transcription. Cells were transiently (24 h) treated with drugs and maintained for an additional 5 days in drug-free
medium. a Immunofluorescence staining of dsRNA using J2 antibody (red) in DMSO-, 5-AZA-, or RRx-001-treated cells. DAPI was used to stain the
nucleus (blue). White arrows point to cells that were negative for dsRNA. b Transcript levels of two ERVs were upregulated by 5-AZA and RRx-001
compared to DMSO as determined by qPCR
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and discontinuations due to hematologic adverse
events, which are typical with 5-AZA, are unlikely with
RRx-001 and, indeed, to date, have not been observed,
resulting in comparatively longer-term treatment. The
inhibition of DNMT1 and DNMT3a expression results
in the demethylation of ERV-Fc2 LTR and the subse-
quent upregulation of IFN production by dsRNA sens-
ing. In addition, Peng et al. showed that DNA
methylation represses tumor production of CXCL9 and
CXCL10 [25]. Treatment with epigenetic modulators
removes the repression and increases effector T cell
tumor infiltration, slows down tumor progression, and
improves the therapeutic efficacy of PD-L1 checkpoint
blockade and adoptive T cell transfusion in tumor-
bearing mice [25]. Moreover, stimulation of IFN
response has been shown to be one of the major mech-
anisms by which chemotherapeutic drugs enhance
anticancer immune responses [26, 27]. The intrinsic an-
titumor effects of IFNs include regulating the expres-
sion of many genes that directly affect tumor cell
proliferation, differentiation, survival, migration, and
other specialized functions and upregulating tumor an-
tigens on tumor cells as well as antigen presentation by
major histocompatibility complexes (MHCs) [28, 29].
In addition, IFNs exert extrinsic antitumor effects by
regulating the activity of almost all immune cell types
(including macrophages, dendritic cells, B cells, T cells,
and innate lymphocytes), creating a well-orchestrated
immune response to counter infectious and malignant
disease [29]. Given their pleiotropic actions, it is not
surprising that the intratumoral expression levels of IFNs
or of ISGs correlated with favorable disease outcome in
several cohorts of patients with cancer [28]. However, IFN
signaling is known to induce a compensatory upregulation
Fig. 5 RRx-001 induced ERV-Fc2-env expression through DNA demethylation. Cells were transiently (24 h) treated with drugs and maintained for an
additional 5 days in drug-free medium. a Transcript levels of ERV-Fc2-env were upregulated by 5-AZA and RRx-001 compared to DMSO as determined
by qPCR. b Methylation of ERV-Fc2 LTR was decreased by 5-AZA and RRx-001 compared to DMSO as determined by methylation-specific PCR. c
Methylation of ERV-Fc2 LTR was decreased by 5-AZA and RRx-001 compared to DMSO as determined by COBRA. Bisulfite-treated DNA was amplified
and digested with the AciI enzyme. Unmethylated DNA (U) was not digested and remained intact as a 199 bp band. Methylated DNA (M) was
digested into two bands (155 and 44 bp). Signal intensity was quantified using ImageJ software (https://imagej.net)
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of immunosuppressive cytokines and receptors [30],
which perhaps lends a note of caution to the use of IFN-
stimulating agents in cancer.
A number of important characteristics of RRx-001 make
it an attractive partner for immunotherapy. First, in
addition to its remarkably benign safety profile in human
and animal studies [14], emerging data suggest that RRx-
001 may also protect normal tissues against some of the
deleterious side effects of immuno-, chemo- or radiother-
apy, such as diarrhea and myelosuppression, thereby
improving therapeutic index. Second, the lack of immune
cell infiltration into tumors has been cited as one reason
for failure of immunotherapy, and normalization of vascu-
lature may improve trafficking of T cells into tumors [31].
RRx-001 has been shown to improve vascularity of murine
tumors by redistributing blood flow [32]. Finally, HDAC
inhibitors promote antitumor immunity and are being
tested in clinical trials in combination with checkpoint
inhibitors. Although not explored in this study, we have
preliminary evidence that RRx-001 is an inhibitor of
histone deacetylases as well as of DNA methyltransferases
[13]. Taken together, this study suggests that RRx-001 via
multiple mechanisms including epigenetic inhibition may
improve immune activity, supporting its development as a
primer to potentiate the efficacy of currently available an-
ticancer modalities including checkpoint inhibitor-based
immunotherapy.
Conclusions
RRx-001 is an immunomodulatory anticancer agent with
multiple mechanisms of action, including induction of
interferon-stimulated genes through viral mimicry, which
refers to the establishment of a “pseudo-infected” state,
against which the immune system mounts a response.
Because RRx-001 is immunomodulatory but lacks the tox-
icity of standard chemotherapeutics, epigenetic agents,
and checkpoint inhibitors, it has the potential to amplify
their activity without increasing toxicity.
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